Records containing: Migraine
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-10-14A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
-
CLINICAL_TRIALS study record update · 2026-10-14A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
-
CLINICAL_TRIALS study record update · 2026-10-14Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine
-
CLINICAL_TRIALS study record update · 2026-10-14A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
-
CLINICAL_TRIALS study record update · 2026-10-14A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-09-21A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
-
CLINICAL_TRIALS study record update · 2026-09-21A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
-
CLINICAL_TRIALS study record update · 2026-09-11Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE)
-
CLINICAL_TRIALS study results posted · 2026-09-03A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants
-
CLINICAL_TRIALS study results posted · 2026-09-02Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
-
CLINICAL_TRIALS study results posted · 2026-08-27A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-FInding Study of Elismetrep (K-304) in the Treatment of Acute Migraine
-
CLINICAL_TRIALS study record update · 2026-08-27A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-FInding Study of Elismetrep (K-304) in the Treatment of Acute Migraine
-
CLINICAL_TRIALS study results posted · 2026-07-24A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
-
CLINICAL_TRIALS study results posted · 2026-07-02A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)
-
CLINICAL_TRIALS study results posted · 2026-07-02Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids in Pediatric Migraine Patients
-
CLINICAL_TRIALS study record update · 2026-07-02A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)
-
CLINICAL_TRIALS study results posted · 2026-06-25A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
-
CLINICAL_TRIALS study results posted · 2026-06-11A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study With An Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects With Episodic Migraine
-
CLINICAL_TRIALS study results posted · 2026-06-09GORE® CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to Evaluate the Safety and Efficacy of Transcatheter Closure of Patent Foramen Ovale for Relief of Migraine Headaches
-
CLINICAL_TRIALS study record update · 2026-04-27Prospective, Randomized, Double-blinded, Placebo-controlled, Cross-over Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) Towards the Ipsilateral Pterygopalatine Fossa for the Treatment of Craniofacial Pain
-
CLINICAL_TRIALS study record update · 2026-04-24Patterned Multichannel Vibratory Coordinated Reset (VCR) Stimulation for the Treatment of Chronic Pain
-
CLINICAL_TRIALS study record update · 2026-04-22BE WELL With Migraine: Brain Education and WELLness With Migraine
-
CLINICAL_TRIALS study record update · 2026-04-22Investigation of Imagery Abilities in Individuals With Migraine and the Relationship Between Imagery Abilities and Proprioception, and Balance
-
CLINICAL_TRIALS study record update · 2026-04-22COMParison of the EffecT of mEdication Therapy: Anticoagulation Versus Anti-platelet Versus Migraine Therapy in Alleviating Migraine With Patent Foramen Ovale
-
CLINICAL_TRIALS study record update · 2026-04-21Treatment for Migraine and Mood (TEAM-M): A Randomized Controlled Trial of a Mindfulness-based Training Program